Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024;17(6):646-651.
doi: 10.1159/000541267. Epub 2024 Sep 16.

Clinically Meaningful Outcomes after 1 Year of Treatment with Setmelanotide in an Adult Patient with a Variant in SH2B1

Juan M Politei  1 , Andrea Patrono  2
Affiliations
Case Reports

Clinically Meaningful Outcomes after 1 Year of Treatment with Setmelanotide in an Adult Patient with a Variant in SH2B1

Juan M Politei et al. Obes Facts. 2024.

Abstract

Introduction: Monogenic obesity is caused by a unique genetic dysfunction, often appears in childhood, and can be accompanied by neuroendocrine, skeletal, developmental, and behavioral disorders, among other manifestations. Some variants in the SH2B1 gene have been suggested as strong candidates for the development of autosomal dominant obesity.

Case presentation: We describe here the clinical response after 1 year of setmelanotide treatment in a 22-year-old patient with an SH2B1 variant. After 3 months of treatment, our patient lost 5.4% of body weight. This period was followed by a 3-month period of noncompliance, in which the patient gained 4% body weight. After reinstating daily drug administration, the patient showed a 19.5% reduction in body weight and a clear improvement in all hunger scales after 1 year of treatment.

Conclusion: These results indicate that the changes seen are drug dependent and provide positive evidence for the administration of setmelanotide in adult patients with heterozygous variants in the SH2B1 gene.

Keywords: Monogenic obesity; SH2B1 variant; Setmelanotide.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1.
Fig. 1.
Body weight course of the patient during childhood and adolescence.
Fig. 2.
Fig. 2.
Body mass index progression during 1 year of treatment. Dotted line represents the period of poor adherence.
See this image and copyright information in PMC

References

    1. González-Jiménez E, Aguilar Cordero M, Padilla López C, García I. Obesidad monogénica humana: papel del sistema leptina-melanocortina en la regulación de la ingesta de alimentos y el peso corporal en humanos. An Sist Sanit Navar. 2012;35(2):285–93. - PubMed
    1. Elks C, den Hoed M, Zhao J, Sharp S, Wareham N, Loos R, et al. . Variability in the heritability of body mass index: a systematic review and meta-regression. Front Endocrinol. 2012;3(3):29. - PMC - PubMed
    1. Foucan L, Larifla L, Durand E, Rambhojan C, Armand C, Michel C, et al. . High prevalence of rare monogenic forms of obesity in obese Guadeloupean Afro-Caribbean children. J Clin Endocrinol Metab. 2018;103(2):539–45. - PubMed
    1. Malhotra S, Sivasubramanian R, Srivastava G. Evaluation and management of early onset genetic obesity in childhood. J Pediatr Genet. 2021;10(3):194–204. - PMC - PubMed
    1. Loos R, Yeo G. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23(2):120–33. - PMC - PubMed

Publication types

MeSH terms